Compare Neurocrine Biosciences Inc (NBIX) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Regeneron Pharmaceuticals Inc trades at $673.67 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4× Neurocrine Biosciences Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | REGN | |
|---|---|---|
Market Cap | $17.40B | $70.47B |
Sector | Health | Health |
52-Week High | $180.55 | $812.27 |
52-Week Low | $123.10 | $545.46 |
Enterprise Value | $16.49B | $64.42B |
Dividend Yield | — | 0.56% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
